Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Deep TMS · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment | EXPERIMENTAL | Deep TMS |
| Name | Type | Description |
|---|---|---|
| Deep TMS | DEVICE | 1Hz Stimulation |
Inclusion Criteria: * SCA3 patients aged 20 - 80 years, with detectable clinical signs and confirmed genetic diagnosis. Exclusion Criteria: 1. Patients who have concomitant epilepsy. 2. History of seizure or heat convulsion. 3. Patients on neuroleptics. 4. Patients with dementia (MMSE\<25) or any...
Deep TMS is an investigational therapy being studied for the treatment of cerebellar signs in patients with Machado Joseph Disease (SCA3), a rare genetic neurodegenerative disorder. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities for this indication.
Deep TMS is being developed by BrainsWay Ltd., a company traded on the stock market under the ticker symbol BWAY. The company is conducting clinical research to evaluate the safety and efficacy of Deep TMS for the treatment of cerebellar signs in patients with Machado Joseph Disease (SCA3).
Deep TMS is in Phase 2 clinical development for the treatment of cerebellar signs in patients with Machado Joseph Disease (SCA3). It is an investigational therapy, meaning it has not yet received regulatory approval and is still undergoing clinical evaluation to determine its safety and effectiveness.
Deep TMS has been studied in one completed Phase 2 clinical trial with the identifier NCT02039206, titled "The Influence of Deep TMS on Cerebellar Signs in Patients With Machado Joseph Disease." This trial enrolled 20 participants in Israel and was an uncontrolled, open-label study that did not use randomization or blinding.
Deep TMS is a non-invasive brain stimulation technique that uses magnetic fields to stimulate nerve cells in the brain. It is designed to reach deeper brain structures compared to standard transcranial magnetic stimulation. In the context of Machado Joseph Disease (SCA3), it is being investigated for its potential to influence cerebellar signs.